Endo Announces Appointment of Joseph J. Ciaffoni as President, U.S. Branded Pharmaceuticals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Piper Jaffray Remains Sidelined on Endo Int'l (ENDP) Following 2Q Beat
August 9, 2016 8:59 AM EDTPiper Jaffray reiterated a Neutral rating on Endo International plc (NASDAQ: ENDP), and raised the price target to $19.00 (from $18.00), following the company's 2Q earnings report. ENDP reported non-GAAP diluted EPS of $0.86 on revenue of $921M, compared to Street estimates of $0.74 and $864M, respectively.
Analyst David Amsellem commented, "Endo reported 2Q16... More
Endo Int'l (ENDP) Tops Q2 EPS by 12c, Affirms Guidance
August 8, 2016 4:32 PM EDTEndo Int'l (NASDAQ: ENDP) reported Q2 EPS of $0.86, $0.12 better than the analyst estimate of $0.74. Revenue for the quarter came in at $921 million versus the consensus estimate of $864.34 million.
Company affirms full year 2016 revenue and adjusted diluted EPS financial guidance.
Company expands management... More
